DailyStocks Stock Article Search

https://www.fool.com/investing/2023/12/13/1-biotech-stock-that-could-be-the-next-amgen/?source=iedfolrf0000001 Dec 13, 2023 - The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 0

https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/?source=iedfolrf0000001 Dec 29, 2023 - There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024. 0

https://www.fool.com/investing/2024/01/29/is-amgen-a-good-dividend-stock-to-buy-right-now/?source=iedfolrf0000001 Jan 29, 2024 - Its diverse product mix and strong fundamentals make a decent case. 0

https://seekingalpha.com/article/4668054-amgen-inc-amgn-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Feb 06, 2024 - Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q4 2023 Earnings Conference Call February 6, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway -... 0

https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001 Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 0

https://www.zacks.com/stock/news/2199629/amgen-amgn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2199629 Dec 18, 2023 - Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close. 0

https://www.zacks.com/stock/news/2200407/can-dogs-of-the-dow-etfs-snap-losing-trend-in-2024?cid=CS-ZC-FT-etf_news_and_commentary-2200407 Dec 20, 2023 - The Dogs of the Dow underperformed the broader market in 2023. However, with the Fed likely to cut rates in 2024, can these dividend dogs roar next year? 0

https://www.zacks.com/stock/news/2203216/coherus-chrs-stock-rallies-on-fda-nod-for-udenyca-onbody?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2203216 Dec 28, 2023 - The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. 0

https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmy-s-krtx-and-ryzb-acquisition-cytk-surges-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2203052 Dec 28, 2023 - Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively. 0

https://www.zacks.com/stock/news/2205532/here-s-how-much-a-1000-investment-in-amgen-made-10-years-ago-would-be-worth-today?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2205532 Jan 04, 2024 - Holding on to popular or trending stocks for the long-term can make your portfolio a winner. 0